CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
$4.60M
Mr. John Michael Climaco Esq., J.D.
3.00
Houston, TX
Nov 08, 2019
0.00
$-367.38
0.13
0.26
-274,505.30%
-0.53
-0.00
-2.10
482.40
0.13
-1,051.49%
857.24%
Similar stocks (11)
Immix Biopharma, Inc.
IMMX
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
AVROBIO, Inc.
AVRO
Sonnet BioTherapeutics Holdings, Inc.
SONN
Enveric Biosciences, Inc.
ENVB
Hepion Pharmaceuticals, Inc.
HEPA
ZyVersa Therapeutics, Inc.
ZVSA
CohBar, Inc.
CWBR
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (11)
Immix Biopharma, Inc.
IMMX
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
AVROBIO, Inc.
AVRO
Sonnet BioTherapeutics Holdings, Inc.
SONN
Enveric Biosciences, Inc.
ENVB
Hepion Pharmaceuticals, Inc.
HEPA
ZyVersa Therapeutics, Inc.
ZVSA
CohBar, Inc.
CWBR
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%